Inhibrx Biosciences Inc(INBX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 5:26 PM ET (Korea 9/12 06:26)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -8.88 | Insider Own | 25.14% | Shs Outstand | 14.7M | Perf Week | -10.62% |
| Market Cap | 1.61B | Forward P/E | - | EPS next Y | 6.09% | Insider Trans | 0.86% | Shs Float | 11.0M | Perf Month | 11.09% |
| Enterprise Value | 1.66B | PEG | - | EPS next Q | -2.45 | Inst Own | 87.78% | Short Float | 29.93% | Perf Quarter | 16.82% |
| Income | -0.14B | P/S | - | EPS this Y | -5.27% | Inst Trans | 18.89% | Short Ratio | 10.27 | Perf Half Y | 57.68% |
| Sales | 0.00B | P/B | - | EPS next 5Y | 15.68% | ROA | -75.44% | Short Interest | 3.30M | Perf YTD | 38.32% |
| Book/sh | -3.6 | P/C | 12.06 | EPS past 3/5Y | 3.4% - | ROE | -1773.6% | 52W High | -29.63% ($155.29) | Perf Year | 284.08% |
| Cash/sh | 9.06 | P/FCF | - | Sales past 3/5Y | -15.98% - | ROIC | -109.53% | 52W Low | 317.22% ($26.19) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 19.23% | Gross Margin | - | Volatility(W/M) | 11.36% 9.13% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | -100% | Oper. Margin | - | ATR (14) | 8.86 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 5.07 | EPS Q/Q | -26.26% | Profit Margin | - | RSI (14) | 50.28 | Recom | 1.5 |
| Dividend Gr. 3/5Y | - | Current Ratio | 5.07 | Sales Q/Q | -100% | SMA20 | -2.75% ($112.36) | Beta | 3.79 | Target Price | $266.67 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/13 | SMA50 | 10.88% ($98.55) | Rel Volume | 0.66 | Prev Close | $111.42 |
| Employees | 110 | LT Debt/Eq | - | EPS/Sales Surpr. | -2.63% - | SMA200 | 21.97% ($89.59) | Avg Volume(3M) | 0.32M | Price | $109.27 |
| IPO | 2024/5/29 | Option/Short | Yes/Yes | Trades | 5713 | Volume | 210,864 | Change | -1.93% |
Company
INBX is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 Inhibrx Biosciences (INBX) is a US-based, clinical-stage biotechnology company. It develops new drug candidates in oncology and immuno-oncology based on a multivalent antibody format, and it holds a protein therapeutics platform that targets death receptors and immune-stimulating targets. Its value is shaped primarily around late-stage clinical data from its core assets.
Over the past 1 year, roughly in the middle
30% below its 1-year high.
INBX has weak earning power
Tap to view numbers
Growth is moderate
Earnings are expected to grow by -5.3% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Short interest is a burden
Institutions hold 87.8%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
BBC 0.01%
FYC 0.01%
DWAS 0.01%
CANC 0.01%
FYX 0.00%It ranks #4 in the industry
Based on market cap of $2B.
INBX $2B PER -
VRTX $131B PER 30.0
REGN $80B PER 19.3
ARGX $62B PER 37.5
FAQ
What kind of company is INBX?
INBX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of INBX?
The market cap of INBX is approximately $1.6B, ranking 2,292 within its sector.
What is the 52-week high and low for INBX?
INBX has recorded a 52-week high of $155.29 and a low of $26.19.
